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Abstract 
 
Mutations and polymorphisms of factor H gene (FH1) are known to be closely involved in 
the development of atypical hemolytic uremic syndrome (aHUS).  Several groups have 
identified disease risk mutations and polymorphisms of FH1 for the development of aHUS, 
and have investigated frequencies of aHUS in a number of ethnic groups.  However, such 
studies on Japanese populations are limited.  In the present study, we analyzed FH1 in 
Japanese aHUS patients and healthy volunteers, and examined whether those variants 
impacted on a tendency for the development of aHUS in Japanese populations.  Similar to 
previous studies, we found that a high frequency of FH1 mutations, located in exon 23 of 
FH1, encodes short consensus repeat 20 in C-terminal end of factor H molecule in patients 
with aHUS (40 %), but not in healthy volunteers.  Interestingly, no significant differences 
in frequency of well-known disease risk polymorphisms for aHUS were observed between 
healthy volunteers and aHUS patients.  Our results suggested that although FH1 mutations 
relates to the development of Japanese aHUS in accordance with other ethnic studies, other 
factor may be required for factor H polymorphism to be a risk factor of Japanese aHUS. 
 
Key words: atypical hemolytic syndrome; factor H; genetic analysis; alternative 
complement pathway; hemolytic assay  
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1. Introduction  
 
Hemolytic uremic syndrome (HUS) is a microvasculature disorder characterized by the triad 
of microangiopathic hemolytic anemia, renal failure, and thrombocytopenia, and is mainly 
caused by the enterocolitis with Shiga toxin-producing Eschericia coli of the serotype 
O157:H7 (Karmali et al, 1983; Karmali et al, 1985).  This form, known as typical HUS, has 
a good prognosis, and not often affects family members (Kaplan et al, 1998; Ault, 2000; 
Sánchez-Corral & Melgosa, 2010).  In contrast, atypical HUS (aHUS), characterized by the 
absence of any infection (e.g., Shiga toxin-producing E. coli, Shigella dysenteriae, and 
Streptococcus pneumoniae) and its associated-diarrhea, tends to relapse and have a poor 
prognosis (Kaplan et al, 1998; Ault, 2000; Sánchez-Corral & Melgosa, 2010), and has been 
classified as either sporadic or familial (Kaplan et al, 1975).  Approximately 50% of 
patients with aHUS have mutations in the genes encoding complement regulatory proteins 
[e.g., factor H, membrane cofactor protein (MCP or CD46), factor I, factor B, 
thrombomodulin, and C3] (Atkinson et al, 2005; Caprioli et al, 2006; Delvaeye et al, 2009).  
In particular, the gene coding factor H, FH1, is known to be the most frequently affected in 
the development of aHUS (Caprioli et al, 2006). 
Factor H, a 150-kDa plasma glycoprotein predominantly produced in the liver, consists 
of 20 homologous units of about 60 amino acid residues each, known as short consensus 
repeats (SCRs) or the complement control protein units (Ault, 2000).  Factor H plays a 
critical role in the regulation of the alternative complement activation pathway; i.e., this 
complement component is a cofactor for serine protease factor I in cleaving C3b to its 
inactive form (C3bi) and accelerates decay of the alternative complement pathway C3bBb 
convertase complex (Weiler et al, 1976; Whaley and Ruddy, 1976; Pangburn et al, 1977).  
Several reports demonstrated that anomalous function of factor H, attributed to the mutations 
Factor H in Japanese aHUS patients 5
in FH1, affects the complementary activation and the pathogenesis of aHUS (Pangburn, 
2002; Sánchez-Corral et al, 2004; Ferreira et al, 2007).  Actually, Saunders et al (2006) 
previously demonstrated that the majority of FH1 mutations in patients with aHUS causes 
either single amino acid exchange or premature translation interruption within SCR 20, a 
domain which contains recognition sites for cell surface ligands, and consequently the 
binding avidity of factor H (to C3b, heparin, or endothelial cells) is reduced. 
To date, several linkage analyses have revealed that FH1 is a candidate gene for aHUS, 
because its mutations or polymorphisms could be frequently detectable in aHUS patients 
(Caprioli et al, 2001; Richards et al, 2001; Caprioli et al, 2003; Neumann, et al, 2003; 
Esparza-Gordillo et al, 2005).  However, to our knowledge, the frequency of FH1 
mutations and polymorphisms and their relation to aHUS in Japanese subjects have not been 
well-defined.  
We designed this study with an aim to characterize factor H and its impact on the 
clinical phenotype in Japanese aHUS patients.  Further, we analyzed the frequency of FH1 
mutations and polymorphisms in Japanese patients with aHUS, their family members, and 
healthy volunteers to clarify its relevance to the pathogenesis of aHUS.   
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2. Materials and Methods 
 
2.1. Subjects 
DNA samples were extracted from whole peripheral blood leukocytes obtained from aHUS 
patients [n=10, 3 men and 7 women; age range 1-40 years (mean ± SE, 19 ±5 years)], 
the family members (for the pedigree analysis), and healthy volunteers [n=15, 3 men and 12 
women; age range 26-58 years (mean ± SE, 41 ± 3 years)] using QIAamp DNA Blood 
Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions.  We also 
used 32 healthy volunteer’s sera for hemolytic assay.  As described previously (Scheiring et 
al, 2010), aHUS was clinically defined as non-diarrheal and non-Shiga toxin HUS.  This 
study was approved by the ethics committee of Shinshu University, Japan (approval No., 
221).  All subjects gave their informed consent before participation. 
 
2.2. Serum C3 
The C3 concentrations in the serum were measured by turbidimetric immunoassay method 
(Nittobo, Tokyo, Japan) using a BioMajesty JCA-BM 1650 (JEOL, Tokyo, Japan). 
 
2.3. Quantification of Factor H concentration 
The factor H concentrations in the serum were measured by the ELISA method as described 
previously (Oppermann et al, 1990).  Briefly, commercial polystyrene immunoplates (Nunc, 
Roskilde, Denmark) were coated with anti-human factor H (ANTIBODYSHOP, Gentofte, 
Denmark) in 50 mmol/L sodium bicarbonate, pH 10.6 (1.0 mg protein/L) for 24 h at 4 °C.   
Plates were washed three times with PBS containing 0.5 g/L Tween 20 (PBS-Tween) after 
each of the subsequent incubation steps.  Unoccupied sites were blocked with the blocking 
buffer (NOF Corp., Tokyo, Japan) for 30 min at room temperature.  The prepared 
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calibrators and samples were then added at 100 μL/well and incubated for 2 h at room 
temperature.  Biotinylated anti-factor H (ANTIBODYSHOP, Gentofte, Denmark) was 
added at 100 μL/well and incubated for 1 h at room temperature.  Horseradish 
peroxidase-conjugated streptoavidin (Dako, Glostrup, Denmark), diluted 1,000-fold with 
PBS-Tween, was then added at 100 μL/well and incubated for 1 h at room temperature.  
After final washings, the color reaction was developed with 100 μL/well of 5 g/L 
t-methylbenzidine dihydrochloride and hydrogen peroxide.  After 30-min incubation at 
room temperature, the reaction was stopped by adding 50 μL of 0.4 mol/L sulfuric acid, and 
the absorbance at 450 nm was measured using Personal LAB (Biochem ImmunoSystems, 
PA).  A calibration curve was generated, and the factor H concentration in serum was 
calculated from the curve.  Each assay was carried out at lest in duplicate.   
 
2.4. Hemolytic assay  
A hemolytic assay was carried out as described previously (Pangburn, 2002) with a small 
modification.  Briefly, sheep erythrocytes were suspended in HEPES buffer (20 mM 
HEPES, 7 mM MgCl2, 10 mM EGTA, 144 mM NaCl, 1% BSA; pH 7.4) to give a final 
concentration of 5×104 cells/L.  One hundred microliters of the above suspension was 
mixed with equal volume of serial dilution series of each serum (5, 10, 20, 30, 40, and 50% 
serum concentration) or saline as a blank, and the mixture was immediately incubated at 
37°C for 30 min.  After the mixture was centrifuged at 3,500 rpm for 3 min at room 
temperature, absorbance at 414 nm (A 414) of the isolated supernatant was determined using 
SpectraMax PLUS384 (Molecular Devices Inc., Sunnyvale, CA).  The percent hemolytic 
activity of each sample was determined by subtracting the A 414 of blank, and dividing by the 
A 414 of the control of total lysis (100 l of serum, 1 l of 5×106 cells/L sheep erythrocytes 
suspension and 99 l of ammonium chloride solution).   
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2.5. Screening for factor H antibody 
The factor H antibodies in the serum were identified by the ELISA method as described 
previously (Dragon-Durey et al, 2005) with a small modification.  Briefly, commercial 
polystyrene immunoplates were coated with human factor H (Calbiochem, Meudon, France) 
in PBS (0.3 g /well) for 24 h at 4 °C.  Plates were washed three times after each of the 
subsequent incubation steps, and blocked unoccupied sites with PBS containing 10 g/L BSA 
for 1 h at room temperature. The samples were added at at 100 μL/well diluted 1:10 for 1 h 
at room temperature.  Horseradish peroxidase-conjugated goat anti-human IgG solution 
(Denka-Seiken, Tokyo, Japan) was then added at 100 μL/well and incubated for 1 h at room 
temperature. After final washings, the color reaction was developed using t-methylbenzidine 
dihydrochloride and hydrogen peroxide.  After 30-min incubation at room temperature, the 
reaction was stopped by adding 100 μL of 0.3 mol/L sulfuric acid, and the absorbance at 450 
nm was measured using Personal LAB.  Absorbance above the mean + 2SD of those 
determined by making measurements of 37 healthy volunteers’ sera was considered as 
positive. 
 
2.6. Screening of FH1 mutations and polymorphisms 
FH1 exons were identically amplified by conventional PCR method.  The primers used in 
present study are listed in Table 1.  We designed 3 specific primer sets which amplify exons 
22 and 23, including C3645T mutation (Ser1191Leu in SCR20) and G3717A mutation 
(Arg1215Gln in SCR20), and 6 specific primer sets used for recognizing polymorphisms 
[(C-257T in promoter region, C994A in exon 7 (Ala307Ala in SCR5), G1492A in exon 9 
(Ala473Ala in SCR8), A2089G in exon 14 (Gln672Gln in SCR11), G2881T in exon 19 
(Glu936Asp in SCR16), and G3364A in exon 20 (Thr1097Thr in SCR18) ] according to 
previous study (Caprioli et al, 2003).  PCR was performed on a Gene Amp PCR system 
Factor H in Japanese aHUS patients 9
9700 (Applied Biosystems, Foster City, CA).  After the purification of PCR products, direct 
DNA sequencing was performed using a BigDyeTM Terminator Cycle Sequencing Ready 
Reaction Kit and an ABI Prism 3100 Genetic Analyzer (both from Applied Biosystems).   
 
2.7. Statistical methods  
All experiments were performed at least three times.  Data are presented as mean ± 2SD.  
Statistical analysis was performed by non-paired t test and chi-square test depending on the 
data set concerned.  A p value of less than 0.05 was accepted as statistically significant.  
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3. Results 
 
3.1. Clinical features of patients with aHUS  
Clinical features and genetic findings of FH1 of 10 patients with aHUS were summarized in 
Table 2 and Table 3, respectively.   
Patient 1 (A-6).  We analyzed for factor H status using patient’s serum, obtained 
after 1-yr from the episode.  Serum factor H level was also significantly decreased (75% of 
healthy volunteer’s serum, p<0.01).  The heterozygous G3717A mutation, and 
heterozygous polymorphisms of C-257T, A2089G, G2881T, and G1492A were found in FH1.  
Anti-factor H antibody was not detected.  Other complement regulatory factors were 
normal (i.e., factor I level was 14.5 mg/dl, and expression of MCP on lymphocytes was not 
decreased).  The ADAMTS13 activity was normal.   
Patient 2 (B-11).  We analyzed for factor H status using patient’s serum, obtained 
after 3-yrs from the first episode.  Factor H level was slightly increased (114% of healthy 
volunteer’s serum, p<0.01).  The heterozygous G3717A mutation, and five heterozygous 
disease risk polymorphisms (C-257T, A2089G, G2881T, C994A, G1492A, and G3364A) 
were found in FH1.  Anti-factor H antibody was not detected.  
Patient 3 (B-12).  We analyzed for factor H status using patient’s serum, obtained 
after 7-yrs from the first episode.  Factor H level was significantly increased (131% of 
healthy volunteer’s serum, p<0.01).  The heterozygous G3717A mutation and two 
heterozygous disease risk polymorphisms (C994A and G1492A) were found in FH1.  In 
addition, we found the novel silent mutation [C3013T (His980His)] in exon 18.  Anti-factor 
H antibody was not detected. 
Patient 4 (C-6).  We analyzed for factor H status using patient’s serum, obtained 
after 2-months from the first episode.  Factor H level was significantly decreased (74% of 
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healthy volunteer’s serum, p<0.01); however, we found neither mutation nor disease risk 
polymorphism of aHUS in FH1.  Anti-factor H antibody was not detected. 
 Patient 5 (D-3).  We analyzed for factor H status using patient’s serum, obtained 
after 4-yrs from the episode.  Factor H level was significantly decreased (64% of healthy 
volunteer’s serum, p<0.01); however, we confirmed that this patient had neither mutation nor 
disease risk polymorphism of aHUS in FH1.  Anti-factor H antibody was not detected. 
Patient 6.  We analyzed for factor H status using patient’s serum, obtained after 
6-months from the episode.  Serum factor H level was significantly decreased (62% of 
healthy volunteer’s serum, p<0.01). We found neither mutation nor disease risk 
polymorphism of aHUS in FH1, however, we could detect anti-factor H antibody. 
Patient 7.  We analyzed for factor H status using patient’s serum, obtained on 
admission.  Although serum factor H level was normal, we found heterozygous 
polymorphisms of A C-257T, C994A, and G3364A in FH1.  Conservative therapy slowly 
improved his clinical condition and increased serum factor H level (138% of healthy 
volunteer’s serum, p<0.01).  Anti-factor H antibody was not detected. 
Patient 8.  We analyzed for factor H status using patient’s serum, obtained on 
admission.  Serum factor H level was significantly increased (145% of healthy volunteer’s 
serum, p<0.01).  The homozygous polymorphisms of C-257T, A2089G, G2881T, and the 
heterozygous G1492A polymorphism were found in FH1.  Furthermore, we found C3645T 
(Ser1191Leu) mutation in exon 23 (data not shown).  Anti-factor H antibody was not 
detected. 
Patient 9.  We analyzed for factor H status using patient’s serum, obtained on 
admission.  Serum factor H level was significantly increased (125% of healthy volunteer’s 
serum, p<0.01).  The homozygous polymorphisms of C-257T, A2089G, G2881T were 
found in FH1.  Anti-factor H antibody was not detected. 
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Patient 10.  We analyzed for factor H status using patient’s serum, obtained on 
admission.  Serum factor H level was also significantly decreased (80% of healthy 
volunteer’s serum, p<0.01).  We found the homozygous polymorphisms of C-257T, 
A2089G, G2881T were found in FH1, and detected anti-factor H antibody. 
 
3.2. Pedigree analysis  
Further, to clarify the impact of factor H genetic status on the development of aHUS, we 
analyzed FH1 mutations and polymorphisms in family members of above 5 patients, and 
investigated their clinical histories. 
Family A.  The pedigree of family A is shown in Fig. 1A.  We identified that a 
G3717A mutation of the proband [A-6 (Patient 1)] was inherited from a paternal allele (A-4), 
and that all three polymorphisms (C-257T, A2089G, G1492A) was from a maternal allele 
(A-5).  The allele sequences of the paternal grandfather (A-1), who died of 
thrombocytopenic purpura (TTP), were able to be determined from those of the paternal 
grandmother (A-2) and a paternal uncle (A-3).  Taken together, a G3717A mutation of the 
proband was proved to have originated from paternal grandfather.  
Family B.  The pedigree of family B is shown in Fig. 1B.  Two probands [B-11 
(Patient 2) and B-12 (Patient 3)] are cousins to each other, and their maternal grandfather 
(B-1) had died of juvenile renal insufficiency at age 42 yrs.  We identified a G3717A 
mutation in both probands (B-11 and B-12) that was inherited from each mother (B-9 and 
B-10), respectively, by taking into consideration of pedigree analysis results and their 
clinical histories, and estimated that the mutation containing the allele originated from B-1.  
Further, we estimated that the three polymorphisms (C-257T, A2089G, and G2881T) of their 
mother’s eldest sister (B-3), who has intermittent episodes of recurrent renal insufficiency, 
were inherited from the other allele of B-1.  The FH1 in B-5 was not able to be determined.  
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B-4, B-6, B-7, and B-8 had already died of other causes.  
Family C.  The pedigree of family C is shown in Fig. 1C.  Similar to the proband 
[C-6 (Patient 4)], her elder brother (C-4, 33-yr-old) and nephew (C-8, 7-yr-old) had been 
diagnosed as aHUS.  However, their FH1 were not able to be analyzed in present study.   
Her mother (C-2) had three heterozygous polymorphisms (C-257T, A2089G, and G2881T), 
but had no episodes of HUS.  Her elder sister (C-3) inherited these three polymorphisms 
without episodes of HUS; whereas, the proband (C-6) did not inherit any of those 
polymorphisms.  
Family D.  The pedigree of family D is shown in Fig. 1D.  The proband’s mother 
(D-2) without episodes of HUS had three heterozygous polymorphisms (C-257T, A2089G, 
and G2881T).  The proband [D-3 (Patient 5)] did not inherit any polymorphisms from her 
mother.  
 
3.3. Biochemical characterization of factor H in aHUS patients 
To characterize factor H in aHUS patients’ sera biochemically, we performed immunoblot 
analysis using specific antibody against factor H.  We detected the main band with a 
molecular weight of 150 kDa, corresponding to factor H protein, and the faint band with a 
molecular weight of 43 kDa, corresponding to factor H-like-protein 1 (Zipfel & Skerka, 
1999; Ault, 2000), in all subjects.  As well as in normal control, no extra band was observed 
in all subjects (data not shown). 
Further, to investigate the function of factor H, we carried out the hemolytic assay 
using sheep erythrocytes as described in Materials and Methods.  The reference value of the 
percent hemolytic activity was determined by making measurements of 32 healthy 
volunteers’ sera.  The individual differences in the percent hemolytic activities were 
minimum at 5% serum concentration among serum dilution series (CV, 14%); thus, we 
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defined the mean hemolytic activity at 5% serum concentration as a provisional reference 
value (mean±2SD, 12 ± 3%).  We then compared the percent hemolytic activity of each 
patient’s serum with the reference value.  Five of 10 aHUS patients (Patient 1, 3, 6, 7, and 
8) presented with a significantly high level of hemolytic activity (Fig.3).  When we added 
recombinant factor H, with a final concentration of 1.1 mg/dl, significantly suppressed the 
accelerated hemolytic activities of 5 all patients (data not shown).  Three of these 5 patients 
(Patient 1, 3, and 8) had mutation in exon 23 that encodes for SCR 20.  Patient 4 had 
neither mutation nor polymorphism, despite having a low level of serum factor H.  Patient 5 
had three heterozygous polymorphisms, but no mutations, with a normal level of serum 
factor H.  On the other hand, although Patient 2 had a mutation in exon 23, his hemolytic 
activity exhibited the normal level.  Overall, no correlation between the hemolytic activity 
and factor H level was observed.  The specificity of a hemolytic assay for the detection of 
aHUS was insufficient (50%), but the sensitivity was 100%.   
 
3.5 Allele frequencies of factor H gene mutations and polymorphisms  
To evaluate the effects of mutations and polymorphisms in FH1 on the development of 
aHUS in Japanese, we compared the frequency of FH1 mutations and polymorphisms in 
aHUS patients with that in healthy volunteers.  As summarized in Table 4, no significant 
differences in the frequencies of all 6 disease risk polymorphisms, identified previously 
(Caprioli et al, 2003), were observed between aHUS patients and healthy volunteers. 
However, the mutations in exon 23 of FH1 (A3717G or C3645T) were highly frequent, but 
not statistically significant, detected in aHUS patients (40%).  
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4. Discussion 
 
In the present study, we identified FH1 mutation in 4 of 10 aHUS patients.  All of those 
mutations, located in exon 23 of FH1, encode SCR 20 (3 Arg1215Gln mutations and 1 
Ser1191Leu mutation).  Previous studies demonstrated that the majority of the mutations 
associated with aHUS are clustered at the SCR 20 in C-terminal end of factor H molecule, 
which plays a critical role as both C3 (C3d fragment)- and heparin-binding sites (Blackmore 
et al, 1998; Ault, 2000; Caprioli et al, 2001).  Three of these patients presented with a 
significantly high level of hemolytic activity.  The serum factor H level of Patient 1 was 
only modestly decreased, and those of Patient 3 and Patient 8 were increased rather than 
decreased.  These findings supported the notion that those mutations in SCR 20 may impair 
the function of factor H in the alternative complement cascade on cell surface (Rodríguez de 
Córdoba et al, 2004) and subsequently cause the development of aHUS.  
Hemolytic assays using sheep erythrocytes have been thought to be useful for the 
detection of factor H-related complement regulatory defects and molecular diagnosis of 
factor H-related aHUS (Sánchez-Corral et al, 2004).  Notably, however, we revealed 
several discrepancies between the existence of the FH1 mutation and the results of hemolytic 
assays in three cases.  First, two patients (Patient 6 and Patient 7) presented with 
significantly high levels of hemolytic activity, even though they had no mutations in the 
well-known hot spot of FH1.  In case of Patient 6, autoantibody may possibly interfere with 
the reaction on the quantification of serum factor H as described previously (Dragon-Durey 
et al, 2005; Józsi et al, 2007).  It differed from Patient 6 with a low level of serum factor H, 
interestingly, Patient 7 presented with a normal level of serum factor H.  Although we could 
not exclude the influence of some medical treatments (especially, plasma infusion) on 
specimens, used for the quantification of serum factor H, the addition of recombinat factor H 
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markedly improved hemolytic activities of both patients, providing compelling evidence that 
these patients have factor H-related complement regulatory defects, attributed to some 
variants in other region of FH1, which were not analyzed in present study.  In general, 
mutations are categorized into the type I mutations with a significant reduction of the coded 
proteins and the type II mutations with an anomalous activity of the coded proteins.  Our 
findings suggested that Patient 7 possibly carry some type II mutations.  Second, despite 
the presence of Arg1215Gln mutation in SCR 20, one patient (Patient 2) presented with a 
normal or slightly high level of hemolytic activity.  While the reduction of serum C3 in this 
patient arguably indicated that a complementary pathway was excessively activated, serum 
factor H level in this patient was slightly increased; thus, one possible reason for this 
discrepancy is that the dysfunction of innate factor H may cause up-regulation of factor H 
production, even an immature one.  Further studies will be necessary to clarify the reason 
for these discrepancies.   
 We showed that 4 of 10 aHUS patients presented with normal levels of hemolytic 
activity and without any mutations in SCR 20.  We could detect anti-factor H antibody in 
serum of Patient 10; therefore, autoantibody may possibly interfere with the reaction on the 
quantification of serum factor H.  Although the pathogenesis of Patient 9 was difficult to 
interpret only by the results of the present study, those of other 2 patients (Patient 4 and 5) 
could be supposed to be caused by the reduction of serum factor H level.  This finding 
suggests the possibility that the production of mature factor H protein might be impaired by 
some FH1 abnormality, such as aberrations in alternative splicing, based on the mutation in 
the region of FH1 introns.  Atkinson et al. (2005) previously demonstrated that 
approximately 50% of patients with aHUS have a mutation in one of three genes, encoding 
factor H (20-30%), MCP (10-20%), or factor I (10-20%).  Hence, we also should take 
account of the aberrations in other complementary regulatory factors, and so it will be 
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necessary to do additional experiments. 
The results of pedigree analysis for family A and B also supported the notion that a 
mutation in the region of FH1, encoding SCR 20 of factor H, could be one of potent 
causative risk factors for the development of aHUS, although the proband’s father (A-4) in 
family A and both probands’ mother (B-9 and B-10) in family B had no episodes, even 
though they had this mutation.  In contrast, we could not find any remarkable features in 
FH1 in the pedigree analysis for family C and D.  However, as described above, we cannot 
completely deny the factor H dysfunction, derived from some aberration of FH1.  The 
marked reduction of serum factor H level in Patient 4 (C-6) leads to the above conclusions.  
In particular, despite having no episodes, her son (C-9) also presented with marked reduction 
of serum factor H level, suggesting that he might inherit some aberration of FH1 (possibly 
some type I mutations in FH1) from his mother [Patient 4 (C-6)], but not any effects of 
autoantibodies.  Furthermore, the clinical differences between Patient 4 (C-6) and her son 
(C-9) suggested that aberrations of FH1 may not be an independent risk factor for aHUS.  
As described previously (Rodríguez de Córdoba et al, 2004; Noris & Remuzzi, 2009), other 
triggers may promote the development of aHUS.  In fact, Patient 4 (C-6) had relapsed after 
pregnancy and partum.  She also presented with an upper respiratory tract inflammation at 
relapse.  These clinical findings were of importance to clarify the detailed pathogenic 
mechanism of aHUS.   
Caprioli et al. (2003) and Neumann et al. (2003) previously reported that several 
polymorphisms in FH1, so-called disease risk polymorphisms, are frequently detected in 
aHUS patients more than healthy volunteers in Caucasians and German registries, 
respectively.  We examined the allele frequencies of those disease risk polymorphisms in 
Japanese populations (See Materials and Methods).  Of interest, no significant difference in 
frequency of disease risk polymorphisms was observed between healthy volunteers and 
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aHUS patients in Japanese groups, although the present study includes a limitation in that the 
results were obtained from small mass analyses.  Previous studies (Blom et al, 2008; 
Martínez-Barricarte et al, 2008) have demonstrated racial differences in the relevance of a 
polymorphism in the C4b-binding protein, a regulator of the classical pathway of 
complementary activation, in the development of aHUS.  Similarly, our findings suggest 
that ethnicity may affect the linkage between carrying the disease risk polymorphism in 
factor H and the development of aHUS.   
In conclusion, our results are consistent with those of prior studies for other 
populations showing that FH1 mutations relates to the development of Japanese aHUS; 
whereas, of interest, the well-known disease risk polymorphisms of FH1 have been detected 
in most healthy Japanese.  This finding suggested that some ‘second hit’ (e.g., a mutation in 
FH1, unknown polymorphisms in FH1, or variants of other complement regulatory factors) 
may be required for factor H polymorphism to be a risk factor of Japanese aHUS. 
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Figure Legends 
 
Figure 1. Pedigree of families A, B, C, and D.  We analyzed the data for mutations and 
polymorphisms in FH1 as described in Materials and Methods.  Arrows, probands; squares, 
men; circles, women; slashes, deceased; black asterisk, G3717A mutation; central black 
squares, carriers of G3717A mutation. 
 
Figure 2.  Hemolytic assay.  Lysis of sheep erythrocytes by serum obtained from aHUS 
patients [solid circles, Patient 1(with G3717A); open square, Patient 3 (with G3717A), solid 
square, Patient 6 (without mutation); triangles, Patient 7 (without mutation); crosses, Patient 
8 (with C3645T mutation)].  The percent hemolytic activity of 32 healthy volunteers’ sera 
shown (open circles) are mean + 2SD.  (b) Inhibition of the lysis by factor H.  We added 
recombinant factor H to each patients’ serum to give final factor H concentrations of 1.1 
mg/dl.  Lysis (%) [with (shaded bars) or without (open bars) recombinant factor H] was 
determined at 5% serum concentration after a 30-min incubation.  Data are expressed as 
mean ± 2SD from duplicate determinations in each of three separate experiments. *: P <0.05 
and **: P <0.01 compared with the lysis (%) of each patient serum without recombinant 
factor H. 
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Table 1. Primers set for factor H gene (FH1) screening 
Region          SCR    Foward                                                 Reverse 
Promoter         -   5’ – CAAGCACTGCATTCTTGGCA – 3’                  5’ – GCTAGGGAAATTCTCCGTTG – 3’ 
  exon 7  SCR 5            5’ – TTTAACGGATACTTATTTCTGCATTATCC – 3’       5’ – TTCAGAATTAAGAAATGGGTCAAGATATG – 3’ 
  exon 9  SCR 8            5’ – ATAGATATTGAATGGGTTTATTTCTGAA – 3’        5’ – GTTGAGCTGACCATCCATCTTTC – 3’ 
  exon 14 SCR 11           5’ – TATATTGTAAAACAGACAATTTAACC – 3’           5’ – ATACAAAATACAAAAGTTTTGACAAG – 3’ 
  exon 19 SCR 16           5’ – GATGTCATAGTAGCTCCTGTATTGTTTATTT – 3’    5’ – CCACTTACACTTTGAATGAAGAATATTTATC – 3’ 
  exon 20 SCR 18           5’ – CACTTCTTTTTTTTCTATTCAGACACC – 3’          5’ – AGAATTGAATTTTAAGCACCATCAG – 3’ 
  exon 22 SCR 19           5’ – TGAAATATCAGACTCATCACAGA – 3’               5’ – ATACAGTGCTGTGTTTGCG – 3’ 
  exon 23 SCR20 a          5’ – GTTCTGAATAAAGGTGTGCAC – 3’                 5’ – GCCAAACAGAAGCTTTATTC – 3’ 
  exon 23 SCR20 b          5’ – CCCCGTTACACACAAATTCAA – 3’                 5’ – CTACATAGTTGGTTTGGAT – 3’ 
a, upstream region of exon 23.  b, downstream region of exon 23. 
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Table 2. Clinical features of aHUS patients 
Case (Pedigree No)   Age   Gender   Onset age    Clinical findings and evolutions 
 1 (A-6)     1 yr     F      4 mo  Renal insufficiency (BUN, 37 mg/dl; Cre, 2.01 mg/dl) and hypocomplementemia (C3*, 71 mg/dl) 
      Under treatment (plasmapheresis and FFP administration).  
 2 (B-11)    34 yr     M     31 yr         Renal insufficiency (BUN, 54 mg/dl; Cre, 4.10 mg/dl), hemolytic anemia (Hb, 6.5 g/dl, LDH, 2200 U/L),  
      biliruminemia (Bil, 2.5 mg/dl), hypocomplementemia (C3, 57 mg/dl), and thrombocytopenia (Plt, 1.5x104/l).  
      Under treatment (Chronic hemodialysis and plasmapheresis). 
 3 (B-12)    38 yr     F      31 yr  Hypocomplementemia (C3, 67 mg/dl).  Under treatment (Chronic hemodialysis).  
 4 (C-6)    29 yr     F      6 mo  Hemolytic anemia (Hb, 11.0 g/dl; LDH, 2083 U/L), and thrombocytopenia (Plt, 1.6x104/l). C3 level was normal. 
      Recurrence of aHUS after pregnancy and partum. Remission after PSL administration and steroid pulse therapy. 
 5 (D-3)    17 yr     F      13 yr  Renal insufficiency (BUN, 73 mg/dl;Cre, 4.30 mg/dl), hemolytic anemia (Hb, 7.6 g/dl; LDH, 2744 U/L),  
      bilirubinemia (Bil, 6.4 mg/dl), and thrombocytopenia (Plt, 1.4x104/l). C3 level was normal. 
      Remission after continuous hemodialysis. 
 6     4 yr     F       n.c.  Renal insufficiency (BUN, 35 mg/dl; Cre, 4.79 mg/dl), hemolytic anemia (Hb, 8.7 g/dl; LDH, 1442 U/L), and  
      thrombocytopenia (Plt, 4.9x104/l). C3 level was normal.  Under treatment (plasmapheresis). 
 7     8 yr     M      4 yr  Recurrence of aHUS after infection of influenzavirus B.  Renal insufficiency (BUN, 55 mg/dl; Cre, 1.70 mg/dl),  
      hemolytic anemia (Hb, 11.8 g/dl; LDH, 2547 U/L), bilirubinemia (Bil, 3.4 mg/dl), thrombocytopenia (Plt,  
      1.2x104/l) and hypocomplementemia (C3, 50 mg/dl).  Under supportive treatment. 
 8    40 yr     M     40 yr  Renal insufficiency (BUN, 106 mg/dl; Cre, 20.73 mg/dl), and hemolytic anemia (Hb, 5.0 g/dl; LDH, 2034 U/L) 
      C3 level was normal.  Under treatment (hemodialysis, plasmapheresis, PSL administration, and steroid pulse therapy). 
 9     7 yr     F      7 mo  Severe thrombocytopenia (Plt, 1.0x104/l).  C3 level was normal. Recurrence. Before treatment. 
 10          9 yr       F      n.c. Renal insufficiency (BUN, 126 mg/dl;Cre, 2.90 mg/dl), hemolytic anemia (Hb, 5.2 g/dl; LDH, 4241 U/L),  
      and thrombocytopenia (Plt, 5.5x104/l) and hypocomplementemia (C3, 23 mg/dl).  Before treatment.  
*,C3 reference range (86.0-160 mg/dl);. Cre, creatinine; Bil, bilirubin; Plt, platelet; FFP, fresh frozen plasama; PSL, prednisolone; n.c., not clear. 
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Table 3.  Factor H status in Japanese aHUS   
  Case (Pedigree No)                   Polymorphisms                        Mutation   Serum factor H levels   Hemolytic activity b  anti-factor H antibody  
C-257T   C994A   G1492A   A2089G   G2881T   G3364A  G3717A  (relative to normal value %) a    
 1 (A-6)     CT       CC       GA       AG       GT       GG     AG   75*  +  - 
 2 (B-11)     CT       CA       GA       AG       GT       GG     AG   114*  -  - 
 3 (B-12)     CC       CA       GA       AA       GG       GG     AG   131*  +  - 
 4 (C-6)     CC       CC       AA       AA       GG       GG     GG   74*  -  - 
 5 (D-3)     CC       CC       AA       AA       GG       GG     GG   n.t.  -  - 
 6     CC       CC       AA       AA       GG       GG     GG   62*  +  + 
 7     CT       CA       n.d.       AA       GG       GA     GG   108  +  - 
 8     TT       CC       GA       GG       TT       GG     GG   143*  +  - 
  9     TT       CC       GG       GG       TT       GA     GG   125*  -  - 
 10     TT       CC       GG       GG       TT       GA     GG   80*  -  + 
 a, Serum factor H levels were expressed as the relative to normal value (1388±547 mg/l), determined by making measurements of healthy volunteers’ sera.   
 *p< 0.01 vs normal value.  b, The percent hemolytic activity of each patient’s serum was compared with those of normal value, determined by making measurements 
 of 32 healthy volunteers’ sera as described in Materials and Methods.  The subjects with a significantly high level of hemolytic activity were expressed as     
 “positive”.  n.d., not determined. n.t., not teted. 
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